0 stringlengths 12 494 | embeddings listlengths 384 384 |
|---|---|
2; however, losing weight is\nnot recommended because of the in-creased risk of small-for-gestational ageinfants (21).\nOptimal glycemic goals are often easier | [
0.021658504381775856,
0.07152189314365387,
-0.02379528060555458,
0.07563228160142899,
0.025970062240958214,
0.06590009480714798,
0.04174495115876198,
0.07825173437595367,
-0.04996693506836891,
0.005853351205587387,
-0.02136106602847576,
-0.041584648191928864,
-0.027236642315983772,
-0.0457... |
to achieve during pregnancy with type 2diabetes than with type 1 diabetes butcan require much higher doses of insulin,sometimes necessitating concentratedinsulin formulations. Insulin is the pre-ferred treatment for type 2 diabetes inpregnancy. An RCT of metformin added toinsulin for the treatment of type 2 diabe-tes f... | [
-0.05753416568040848,
-0.0023918705992400646,
-0.08343325555324554,
0.05454547330737114,
0.0007787861977703869,
0.0015340492827817798,
0.060305725783109665,
0.11435171216726303,
-0.021297216415405273,
-0.011037308722734451,
-0.08113174140453339,
0.030086833983659744,
-0.09522538632154465,
... |
for the treatment of type 2 diabe-tes found less maternal weight gain andfewer cesarean births. There were fewermacrosomic neonates, but there wasa doubling of small-for-gestational-ageS288 Management of Diabetes in Pregnancy Diabetes Care Volume 47, Supplement 1, January 2024 | [
-0.03144768998026848,
0.05295857414603233,
-0.06488237529993057,
0.059671808034181595,
-0.022801358252763748,
-0.002666445914655924,
-0.016822177916765213,
0.09363735467195511,
-0.00821617804467678,
0.02013596147298813,
-0.036981020122766495,
0.005415943916887045,
-0.09294554591178894,
-0.... |
©AmericanDiabetesAssociation | [
0.06342031806707382,
-0.04462772607803345,
-0.07223597913980484,
0.043682683259248734,
-0.045854225754737854,
-0.0014199750730767846,
-0.005912777967751026,
-0.07833275198936462,
-0.04720243066549301,
0.09212949872016907,
0.0628901943564415,
-0.04908110201358795,
0.0067015099339187145,
0.0... |
neonates (112). As in type 1 diabetes, insu-\nlin requirements drop dramatically afterdelivery.\nThe risk for associated hypertension\nand other comorbidities may be as highor higher with type 2 diabetes com-\npared with type 1 diabetes, even if dia-\nbetes is better managed and of shorter\napparent duration, with preg... | [
-0.01925830915570259,
0.01898471638560295,
-0.06797536462545395,
0.03168186917901039,
0.03653765842318535,
0.03645449876785278,
-0.0028296622913330793,
0.08309732377529144,
-0.10180499404668808,
-0.011220633052289486,
0.008483396843075752,
0.048972420394420624,
-0.09065458178520203,
-0.026... |
apparent duration, with pregnancy loss\nappearing to be more prevalent in the\nthird trimester in those with type 2 dia-\nbetes, compared with the first trimester\nin those with type 1 diabetes (113,114).\nPREECLAMPSIA AND ASPIRIN\nRecommendation\n15.20 Pregnant individuals with type 1\nor type 2 diabetes should be pre-... | [
-0.015027623623609543,
-0.0012749246088787913,
-0.05325634405016899,
0.08859112113714218,
0.012459548190236092,
0.001950498204678297,
0.004287366755306721,
0.11018069088459015,
0.02674705535173416,
-0.02400493063032627,
-0.052325889468193054,
-0.01026503648608923,
-0.10056237876415253,
-0.... |
day starting at 12 to 16 weeks of ges-tation to lower the risk of preeclamp-sia.EA dosage of 162 mg/day may\nbe acceptable; Ecurrently, in the\nU.S., low-dose aspirin is available in81-mg tablets.\nDiabetes in pregnancy is associated withan increased risk of preeclampsia (115).The U.S. Preventive Services Task Force | [
-0.033196911215782166,
0.06091233715415001,
-0.05283937603235245,
0.04029310867190361,
-0.04610031470656395,
0.03226254880428314,
0.041028667241334915,
0.12902601063251495,
0.0032061159145087004,
-0.012195723131299019,
0.03808183968067169,
0.042542364448308945,
-0.09120193123817444,
-0.006... |
recommends using low-dose aspirin (81\nmg/day) as a preventive medication at\n12 weeks of gestation in individuals at\nhigh risk for preeclampsia, such as those\nwith type 1 or type 2 diabetes (116).\nHowever, a meta-analysis and an addi-\ntional trial demonstrate that low-dose\naspirin <100 mg is not effective in re- | [
-0.03390789404511452,
0.041249435395002365,
-0.007575402036309242,
0.07856673002243042,
-0.04792183265089989,
0.05163309723138809,
0.019667889922857285,
0.14469483494758606,
-0.006212092004716396,
-0.02200913056731224,
0.004930216819047928,
0.06299590319395065,
-0.10825493186712265,
-0.014... |
aspirin <100 mg is not effective in re-\nducing preeclampsia. Low-dose aspirin>100 mg is required (117– 119). A cost-\nbene fit analysis has concluded that\nthis approach would reduce morbidity,save lives, and lower health care costs\n(120). There are insuf ficient data about\nwhether the use of aspirin speci fically | [
-0.0686986893415451,
0.06249406188726425,
-0.018980644643306732,
0.06839919090270996,
-0.08405755460262299,
0.04282250627875328,
-0.003884728066623211,
0.12881611287593842,
0.020744843408465385,
-0.0051607657223939896,
0.04176555573940277,
0.029154526069760323,
-0.07591471821069717,
-0.016... |
whether the use of aspirin speci fically\nin pregnant people with preexisting dia-\nbetes ultimately reduces the incidence\nof preeclampsia (121,122), although a\nmeta-analysis showed that preeclampsia\nreductions occurred with aspirin adminis-\ntration in high-risk groups overall (115).\nIndividuals with GDM may be can... | [
-0.07263503968715668,
0.008904505521059036,
-0.031065847724676132,
0.055773887783288956,
-0.02189788408577442,
0.04578935354948044,
0.06180417910218239,
0.07448039203882217,
0.004911518655717373,
0.02565029077231884,
0.010649057105183601,
0.09559562057256699,
-0.14763592183589935,
-0.00006... |
Individuals with GDM may be candidates\nfor aspirin therapy for preeclampsia pre-\nvention if they have a single high risk fac-\ntor, such as chronic hypertension or anautoimmune disease, or multiple moder-\nate risk factors, such as being nulliparous,\nhaving obesity, being age $35 years, or | [
-0.08475159108638763,
-0.014743244275450706,
0.012659967876970768,
0.030274968594312668,
-0.03871658071875572,
0.03976210951805115,
0.018196268007159233,
0.09732053428888321,
-0.04575929418206215,
0.022539960220456123,
0.030739549547433853,
0.027402175590395927,
-0.11236641556024551,
-0.01... |
having obesity, being age $35 years, or\nother factors per the U.S. PreventiveS e r v i c e sT a s kF o r c e( 1 1 6 ) .M o r es t u d i e sare needed to assess the long-term ef-\nfects of prenatal aspirin exposure on off-spring (121).\nPREGNANCY AND DRUG\nCONSIDERATIONS\nRecommendations\n15.21 In pregnant individuals ... | [
-0.009487117640674114,
-0.012704139575362206,
-0.03790266066789627,
0.07579217851161957,
0.07806599140167236,
0.0866551324725151,
0.018373150378465652,
0.0830354243516922,
-0.04811621084809303,
0.04261508584022522,
0.024818092584609985,
-0.05617319419980049,
-0.09054826200008392,
-0.016703... |
Recommendations\n15.21 In pregnant individuals with dia-\nbetes and chronic hypertension, a\nblood pressure threshold of 140/90\nmmHg for initiation or titration of ther- | [
-0.08846952021121979,
-0.008834106847643852,
-0.05822840332984924,
-0.03138820081949234,
-0.040109552443027496,
-0.03871053084731102,
0.0034329250920563936,
0.05857193097472191,
-0.03795764967799187,
-0.03315269574522972,
0.0283502209931612,
-0.08943115919828415,
-0.08530530333518982,
0.03... |
mmHg for initiation or titration of ther-\na p yi sa s s o c i a t e dw i t hb e t t e rp r e g -nancy outcomes than reservingtreatment for severe hypertension,with no increase in risk of small-for-gestational-age birth weight. AThere\nare limited data on the optimal lower\nlimit, but therapy should be deintensi fied\nf... | [
-0.053446680307388306,
0.071344755589962,
-0.0712348148226738,
-0.033245500177145004,
-0.04586969316005707,
0.045837707817554474,
-0.05980578809976578,
0.1439291536808014,
-0.03951867297291756,
0.004733888432383537,
0.06058341637253761,
-0.05706655979156494,
-0.018859393894672394,
-0.01283... |
for blood pressure <90/60 mmHg. EA\nblood pressure target of 110– 135/\n85 mmHg is suggested in the interestof reducing the risk for accelerated ma-ternal hypertension. A\n15.22 Potentially harmful medica-\ntions in pregnancy (i.e., ACE inhibi- | [
-0.05250389501452446,
0.05692015215754509,
-0.0563226118683815,
0.027368003502488136,
0.027410736307501793,
0.018121059983968735,
0.0009046935592778027,
0.07022768259048462,
-0.0036125746555626392,
0.011407788842916489,
0.04716043546795845,
-0.12145230919122696,
-0.0892275795340538,
-0.065... |
tions in pregnancy (i.e., ACE inhibi-\ntors, angiotensin receptor blockers,statins) should be stopped prior toconception and avoided in sexuallyactive individuals of childbearingpotential who are not using reliable\ncontraception. B\nIn normal pregnancy, blood pressure is | [
-0.09748711436986923,
0.012659179978072643,
-0.08884301781654358,
0.04161667078733444,
0.03975798934698105,
0.07035965472459793,
0.02588139846920967,
0.05831122398376465,
-0.008279320783913136,
0.040994998067617416,
0.067674919962883,
-0.03537854552268982,
-0.1115121841430664,
0.0039725480... |
contraception. B\nIn normal pregnancy, blood pressure is\nlower than in the nonpregnant state.The Chronic Hypertension and Preg-nancy (CHAP) Trial Consortium ’sR C To n\ntreatment for mild chronic hypertensionduring pregnancy demonstrated that\na blood pressure of 140/90 mmHg, as | [
-0.0903358981013298,
0.07410718500614166,
-0.03388556092977524,
0.028656212612986565,
0.030263500288128853,
0.05550065264105797,
0.019454840570688248,
0.03252147138118744,
-0.0006441322038881481,
0.05171167477965355,
0.013341819867491722,
-0.05832095071673393,
-0.08629704266786575,
-0.0639... |
a blood pressure of 140/90 mmHg, as\nthe threshold for initiation or titrationof treatment, reduces the incidence ofadverse pregnancy outcomes withoutcompromising fetal growth (123). TheCHAP Consortium ’s study mitigates con-\ncerns about small-for-gestational-age birth\nweight. Attained mean ± SD blood pres- | [
-0.05123785510659218,
0.09924346208572388,
-0.06893284618854523,
-0.02324378304183483,
-0.0179122481495142,
0.0743061825633049,
-0.045232001692056656,
0.1101171001791954,
-0.052428364753723145,
0.056638095527887344,
0.08774334192276001,
-0.05034642294049263,
-0.026604870334267616,
-0.05729... |
weight. Attained mean ± SD blood pres-\nsure measurements in the treated versusuntreated groups were systolic 129.5 ±10.0 vs. 132.6 ± 10.1 mmHg (between-group difference /C03.11 [95% CI /C03.95 to\n2.28]) and diastolic 79.1 ± 7.4 vs. 81.5 ±8.0 mmHg ( /C02.33 [95% CI /C02.97 to | [
-0.0007563137914985418,
0.05758398398756981,
-0.08017266541719437,
0.015395754016935825,
-0.09710344672203064,
-0.022612731903791428,
-0.0802086666226387,
0.12059836834669113,
-0.0012564138742163777,
-0.07401880621910095,
0.01174073200672865,
-0.05818115174770355,
-0.07294846326112747,
-0.... |
0.04]) (123). Individuals with diabetes hadan even better composite outcome scorethan those without diabetes (123).\nAs a result of the CHAP study, ACOG\nissued a Practice Advisory recommend-ing a blood pressure of 140/90 mmHgas the threshold for initiation or titra- | [
-0.050273019820451736,
0.04704703390598297,
-0.12209717929363251,
0.01386654656380415,
-0.05261450260877609,
0.0229957215487957,
0.06841069459915161,
0.07831674814224243,
-0.04135262966156006,
-0.025284666568040848,
0.03272218629717827,
-0.02505132369697094,
0.0012389984913170338,
-0.00432... |
tion of medical therapy for chronic hy-pertension in pregnancy (124) ratherthan their previously recommendedthreshold of 160/110 mmHg (125).\nThe CHAP study provides additional\nguidance for the management of hyper-tension in pregnancy. Data from the pre-viously published Control of Hypertensionin Pregnancy Study (CHIP... | [
-0.0874992311000824,
0.02069362811744213,
-0.08012370765209198,
0.011901294812560081,
-0.009596777148544788,
-0.019255122169852257,
-0.0038862761575728655,
0.09793173521757126,
-0.043422210961580276,
-0.0525338239967823,
-0.00022935839660931379,
-0.05183761194348335,
-0.05949680879712105,
... |
target blood pressure goal of 110 –135/85\nmmHg to reduce the risk of uncontrolled\nmaternal hypertension and minimize im-paired fetal growth (125 –127). The 2015 | [
-0.03657021000981331,
0.10802943259477615,
-0.0945136547088623,
-0.026455741375684738,
-0.01835923083126545,
0.045620519667863846,
-0.0644521415233612,
0.008057762868702412,
-0.06789414584636688,
0.010268782265484333,
0.023386331275105476,
-0.0814976692199707,
-0.05334021523594856,
-0.0746... |
study (126) excluded pregnancies compli-cated by preexisting diabetes, and only6% of participants had GDM at enroll-ment. There was no difference in preg-nancy loss, neonatal care, or other\nneonatal outcomes between the groups\nwith tighter versus less tight control ofhypertension (126).\nDuring pregnancy, treatment w... | [
-0.020928483456373215,
0.03005348891019821,
-0.0369604267179966,
0.025811217725276947,
-0.00803756806999445,
0.027104506269097328,
-0.02135179191827774,
0.10815394669771194,
-0.019305506721138954,
0.028316380456089973,
-0.006507423706352711,
0.0443379282951355,
-0.0900135189294815,
-0.0855... |
During pregnancy, treatment with ACE\ninhibitors and angiotensin receptor block-\ners is contraindicated because they may\ncause fetal renal dysplasia, oligohydram-nios, pulmonary hypoplasia, and intra-uterine growth restriction (23).\nA large study found that after adjust-\ning for confounders, first trimester ACE | [
-0.06916297972202301,
0.015421640127897263,
-0.04079712927341461,
0.049533743411302567,
0.04621853679418564,
0.020917007699608803,
-0.048757825046777725,
0.08601561933755875,
-0.0031862210016697645,
0.006623466964811087,
0.057983268052339554,
-0.0018973927944898605,
-0.11202137917280197,
-... |
ing for confounders, first trimester ACE\ninhibitor exposure does not appear to beassociated with congenital malforma-tions (128). However, ACE inhibitors and\nangiotensin receptor blockers should be\ns t o p p e da ss o o na sp o s s i b l ei nt h e first | [
-0.04306401312351227,
-0.002801224123686552,
-0.05231683701276779,
0.05508094280958176,
0.0011289475951343775,
0.04994680732488632,
-0.046309493482112885,
0.11187400668859482,
-0.03756473585963249,
0.029826542362570763,
0.08671403676271439,
-0.04697732254862785,
-0.1137080118060112,
-0.021... |
s t o p p e da ss o o na sp o s s i b l ei nt h e first\ntrimester to avoid second and third tri-mester fetopathy (128). Antihypertensivedrugs known to be effective and safe in\npregnancy include methyldopa, nifedi-\npine, labetalol, diltiazem, clonidine, andprazosin. Atenolol is not recommended,but other b-blockers may... | [
-0.029002130031585693,
-0.0053767254576087,
-0.05013120919466019,
-0.04873578995466232,
-0.039208147674798965,
0.04821786656975746,
0.0017528653843328357,
0.1335473209619522,
-0.031278982758522034,
-0.006912195589393377,
-0.036212895065546036,
0.003988521173596382,
-0.027380455285310745,
0... |
necessary. Chronic diuretic use duringpregnancy is not recommended as it hasbeen associated with restricted maternalplasma volume, which may reduce ute-roplacental perfusion (129). On the basis\nof available evidence, statins should also\nbe avoided in pregnancy (130).\nSee pregnancy and antihypertensive\nmedications i... | [
-0.09277042001485825,
0.04616266116499901,
-0.028146641328930855,
0.042209092527627945,
0.05313288792967796,
0.01942344941198826,
-0.02920171245932579,
0.138187438249588,
-0.026521187275648117,
0.018379807472229004,
-0.027301359921693802,
0.03319922834634781,
-0.032882917672395706,
0.02060... |
medications in Section 10, “Cardiovascular\nDisease and Risk Management,” for more\ninformation on managing blood pressurein pregnancy.\nPOSTPARTUM CARE\nRecommendations\n15.23 Insulin resistance decreases\ndramatically immediately postpartum,diabetesjournals.org/care Management of Diabetes in Pregnancy S289\n©American... | [
-0.10034935921430588,
0.06517625600099564,
-0.03639698401093483,
-0.010822495445609093,
0.04041299223899841,
0.016583755612373352,
-0.02539108134806156,
0.02497665211558342,
-0.09560614079236984,
-0.0160045363008976,
-0.05041277036070824,
0.015431559644639492,
-0.0738399475812912,
-0.03490... |
and insulin requirements need to be\nevaluated and adjusted as they are\noften roughly half the prepregnancy\nrequirements for the initial few dayspostpartum. C\n15.24 A contraceptive plan should\nbe discussed and implemented with\nall people with diabetes of childbear-\ning potential. A\n15.25 Screen individuals with ... | [
-0.08743229508399963,
0.10155793279409409,
-0.05573396384716034,
0.0044372789561748505,
-0.020481357350945473,
0.04348316788673401,
0.03419114276766777,
0.06107207387685776,
-0.06822573393583298,
0.02932140603661537,
0.013441088609397411,
0.022277627140283585,
-0.11793256551027298,
-0.0197... |
ing potential. A\n15.25 Screen individuals with a recent\nhistory of GDM at 4 –12 weeks post-\npartum, using the 75-g oral glucosetolerance test and clinically appropri-\nate nonpregnancy diagnostic criteria. B\n15.26 Individuals with overweight/\nobesity and a history of GDM found | [
-0.014891629107296467,
0.021850820630788803,
-0.028306813910603523,
-0.021149545907974243,
-0.03249926492571831,
-0.05833661928772926,
0.061273157596588135,
0.12324241548776627,
-0.054316937923431396,
0.05756131187081337,
-0.008176136761903763,
-0.003761725500226021,
-0.07948551326990128,
... |
15.26 Individuals with overweight/\nobesity and a history of GDM found\nto have prediabetes should receiveintensive lifestyle interventions and/ormetformin to prevent diabetes. A\n15.27 Breastfeeding efforts are rec-\nommended for all individuals withdiabetes. ABreastfeeding is recom- | [
-0.04047640785574913,
0.0159543938934803,
0.02132791467010975,
0.028888890519738197,
-0.011826582252979279,
0.033181916922330856,
0.031779512763023376,
0.0251556858420372,
-0.12401442229747772,
0.0017769819824025035,
0.04486165568232536,
0.03581586852669716,
-0.10672684758901596,
-0.038037... |
ommended for all individuals withdiabetes. ABreastfeeding is recom-\nmended for individuals with a his-tory of GDM for multiple bene fits,A\nincluding a reduced risk for type 2diabetes later in life. B\n15.28 Individuals with a history of\nGDM should have lifelong screeningfor the development of type 2 diabe-tes or pred... | [
-0.013994485139846802,
0.026825562119483948,
-0.03453872352838516,
-0.021797558292746544,
-0.03784235566854477,
0.014816489070653915,
0.09905316680669785,
0.07094429433345795,
-0.0623612254858017,
0.017609016969799995,
-0.0035147322341799736,
0.054677966982126236,
-0.1094990149140358,
-0.0... |
15.29 Individuals with a history of\nGDM should seek preconceptionscreening for diabetes and precon-ception care to identify and treat hy-perglycemia and prevent congenitalmalformations. E\n15.30 Postpartum care should include\npsychosocial assessment and supportfor self-care. E\nGestational Diabetes Mellitus\nPostpart... | [
-0.03534756228327751,
0.06547536700963974,
-0.00579663272947073,
-0.025491980835795403,
-0.05448056384921074,
0.015988890081644058,
0.004485206678509712,
0.07108078896999359,
-0.08374622464179993,
0.010224195197224617,
0.021478287875652313,
-0.001370314508676529,
-0.11933602392673492,
-0.0... |
Gestational Diabetes Mellitus\nPostpartum Care\nBecause GDM often represents previ-\nously undiagnosed prediabetes, type 2diabetes, maturity-onset diabetes of theyoung, or even developing type 1 diabe-tes, individuals with GDM should be\ntested for persistent diabetes or predia-\nbetes at 4 –12 weeks postpartum with a | [
-0.021725621074438095,
0.026207244023680687,
0.004128504078835249,
0.0020064343698322773,
-0.029021525755524635,
-0.003938979469239712,
0.04980781674385071,
0.04582371935248375,
-0.017474055290222168,
0.015315207652747631,
-0.019990520551800728,
0.08666957169771194,
-0.1173756793141365,
-0... |
betes at 4 –12 weeks postpartum with a\nfasting 75-g OGTT using nonpregnancycriteria as outlined in Section 2, “Diagnosis\nand Classi fication of Diabetes, ”specifi cally\nTables 2.1 and 2.2. The OGTT is recom-mended over A1C at 4 –12 weeks postpar- | [
-0.04626759514212608,
0.05222092196345329,
-0.03797471150755882,
0.018864942714571953,
-0.04444052278995514,
-0.02709531970322132,
-0.019958896562457085,
0.08286815881729126,
-0.05188540369272232,
0.02278807945549488,
-0.034437380731105804,
0.028253920376300812,
-0.10016003251075745,
-0.07... |
tum because A1C may be persistentlyimpacted (lowered) by the increased redblood cell turnover related to preg-nancy, by blood loss at delivery, or bythe preceding 3-month glucose pro file.\nT h eO G T Ti sm o r es e n s i t i v ea td e t e c t i n g | [
-0.0807451382279396,
-0.065179243683815,
-0.03486665338277817,
0.06323149800300598,
0.015526332892477512,
0.029575297608971596,
0.025159817188978195,
0.13081467151641846,
0.07591959089040756,
0.05705558881163597,
-0.02936159260571003,
0.030902914702892303,
-0.06795560568571091,
-0.02535118... |
T h eO G T Ti sm o r es e n s i t i v ea td e t e c t i n g\nglucose intolerance, including both predia-betes and diabetes. In the absence of un-equivocal hyperglycemia, a positive screen\nfor diabetes requires two abnormal val-\nues. If both the fasting plasma glucose($126 mg/dL [ $7.0 mmol/L]) and 2-h\nplasma glucose... | [
-0.026340942829847336,
0.08530080318450928,
-0.024343134835362434,
-0.02979954704642296,
-0.06863885372877121,
-0.0011521867709234357,
0.10564038902521133,
0.10687126964330673,
0.0012270647566765547,
0.006370923016220331,
0.005313917528837919,
-0.013135628774762154,
0.0075407493859529495,
... |
plasma glucose ($200 mg/dL [ $11.1\nmmol/L]) are abnormal in a single screen-ing test, then the diagnosis of diabetes ismade. If only one abnormal value in theOGTT meets diabetes criteria, the test\nshould be repeated to confi rm that the\nabnormality persists. OGTT testing imme- | [
-0.0631178766489029,
0.08595426380634308,
-0.010601558722555637,
-0.010206309147179127,
-0.0007335133268497884,
-0.0650964006781578,
0.061599839478731155,
0.1109173521399498,
0.03781949356198311,
-0.013020619750022888,
-0.0306128840893507,
-0.011350025422871113,
-0.028630448505282402,
0.03... |
abnormality persists. OGTT testing imme-\ndiately postpartum, while still hospitalized,has demonstrated improved engagementin testing but also variably reduced sensi-\ntivity to the diagnosis of impaired fasting\nglucose, impaired glucose tolerance, andtype 2 diabetes (131,132).\nIndividuals with a history of GDM shoul... | [
-0.04643968120217323,
0.022009512409567833,
0.008554641157388687,
0.02544592320919037,
0.014657830819487572,
-0.08619912713766098,
0.012369384989142418,
0.11103835701942444,
-0.050064269453287125,
-0.007822533138096333,
0.020713862031698227,
0.05318222567439079,
-0.08181995153427124,
0.013... |
Individuals with a history of GDM should\nhave ongoing screening for prediabetes or\ntype 2 diabetes every 1 –3y e a r s ,e v e ni f\nthe results of the initial 4 –12 week post-\npartum 75-g OGTT are normal. Ongoing\nevaluation may be performed with any rec-\nommended glycemic test (e.g., annual A1C, | [
-0.019847942516207695,
0.053757667541503906,
0.014266891404986382,
-0.013644500635564327,
-0.054231952875852585,
-0.05486193671822548,
0.009051637724041939,
0.05266508832573891,
-0.08052239567041397,
0.012388980947434902,
-0.016376491636037827,
0.06423839926719666,
-0.08461391180753708,
-0... |
ommended glycemic test (e.g., annual A1C,\nannual fasting plasma glucose, or triennial75-g OGTT using thresholds for nonpreg-nant individuals).\nIndividuals with a history of GDM\nhave an increased lifetime maternalrisk for diabetes estimated at 50 –60%\n(133,134), and those with GDM havea 10-fold increased risk of dev... | [
-0.04434895142912865,
0.05872197821736336,
-0.020386187359690666,
0.0035399505868554115,
-0.016450267285108566,
-0.030803505331277847,
-0.0018856795504689217,
0.08842838555574417,
-0.025731263682246208,
0.024053070694208145,
0.023285891860723495,
0.02842845767736435,
-0.09425730258226395,
... |
type 2 diabetes compared with those\nwithout GDM (133). Absolute risk ofdeveloping type 2 diabetes after GDMincreases linearly through a person ’s\nlifetime, being approximately 20% at\n10 years, 30% at 20 years, 40% at 30 years,\n50% at 40 years, and 60% at 50 years(134). In the prospective Nurses ’Health\nStudy II (N... | [
0.028305547311902046,
-0.044664375483989716,
-0.04699284955859184,
0.012128488160669804,
-0.036811817437410355,
0.010481196455657482,
0.02325098030269146,
0.10561434179544449,
-0.0443638414144516,
-0.038893118500709534,
-0.020381629467010498,
0.08018770068883896,
-0.06362158060073853,
0.03... |
Study II (NHS II), subsequent diabetes\nrisk after a history of GDM was signi fi-\ncantly lower in those who followed\nhealthy eating patterns (135). Adjustingfor BMI attenuated this association mod-\nerately, but not completely. Interpreg- | [
0.03572157025337219,
0.030950356274843216,
-0.008934292942285538,
0.027389822527766228,
-0.06225802004337311,
-0.044408999383449554,
0.049331434071063995,
0.06189426779747009,
-0.11535999178886414,
-0.04761742800474167,
0.014943202957510948,
0.010331833735108376,
-0.041007768362760544,
-0.... |
erately, but not completely. Interpreg-\nnancy weight gain is associated withincreased risk of adverse pregnancy out-comes (136) and higher risk of GDM,while in people with BMI >25 kg/m\n2,\nweight loss is associated with lower riskof developing GDM in the subsequentpregnancy (137). Development of type 2diabetes is 18%... | [
0.0026866947300732136,
-0.0034886589273810387,
-0.022510146722197533,
0.05136488750576973,
-0.03512575104832649,
-0.01182149350643158,
0.06534123420715332,
0.09484703093767166,
-0.029812004417181015,
0.0006831889040768147,
0.010874932631850243,
0.025601793080568314,
-0.038096703588962555,
... |
increase from prepregnancy BMI at\nfollow-up, highlighting the importance ofeffective weight management after GDM(138). In addition, postdelivery lifestyle in-terventions are effective in reducing risk oftype 2 diabetes (139).\nBoth metformin and intensive life- | [
-0.06002412736415863,
0.0108562670648098,
-0.0414237305521965,
0.04566216096282005,
-0.0660046860575676,
0.012894939631223679,
0.01271881628781557,
0.10023923963308334,
-0.08547849953174591,
-0.028149360790848732,
-0.04734695702791214,
0.01631738431751728,
-0.07346891611814499,
-0.08187962... |
Both metformin and intensive life-\nstyle intervention prevent or delay pro-gression to diabetes in individuals withprediabetes and a history of GDM. Onlyfive to six individuals with prediabetes | [
-0.0324787013232708,
-0.010352298617362976,
-0.03874557837843895,
0.03804278001189232,
-0.027484333142638206,
0.012026282027363777,
0.007270313799381256,
0.11757896840572357,
-0.015658359974622726,
-0.024786021560430527,
-0.06597056984901428,
0.09425728768110275,
-0.07652542740106583,
0.00... |
and a history of GDM need to be treatedwith either intervention to prevent onecase of diabetes over 3 years (140). Inthese individuals, lifestyle intervention\nand metformin reduced progression to di-\nabetes by 35% and 40%, respectively,over 10 years compared with placebo(141). If the pregnancy has motivated the | [
-0.04682415723800659,
0.01026271004229784,
-0.03131994977593422,
0.020146207883954048,
-0.004881852772086859,
-0.0071721202693879604,
0.0015903261955827475,
0.09185623377561569,
-0.01958283968269825,
0.006601039320230484,
-0.06970279663801193,
0.06678866595029831,
-0.09911900758743286,
-0.... |
adoption of healthy nutrition, building on\nthese gains to support weight loss is rec-ommended in the postpartum period.(See Section 3, “Prevention or Delay of\nDiabetes and Associated Comorbidities. ”)\nIndividuals with prediabetes or a his-\ntory of GDM will need preconceptionevaluation for as long as they have child... | [
-0.032292138785123825,
0.044022735208272934,
-0.021481992676854134,
0.04837581515312195,
-0.011425572447478771,
0.05844482034444809,
0.02071933075785637,
-0.024748116731643677,
-0.057971954345703125,
0.019766271114349365,
0.048102006316185,
0.045741673558950424,
-0.08480575680732727,
-0.08... |
Preexisting Type 1 and Type 2\nDiabetes Postpartum Care\nInsulin sensitivity increases dramatically\nwith the delivery of the placenta. In one\nstudy, insulin requirements in the imme-\ndiate postpartum period are roughly34% lower than prepregnancy insulin re-quirements (142). Insulin sensitivity then\nreturns to prepr... | [
0.0078052254393696785,
-0.04498450830578804,
-0.03776009753346443,
0.06657722592353821,
0.03384177386760712,
-0.03034915216267109,
0.0694475919008255,
0.08211471885442734,
-0.05662878602743149,
-0.01197662390768528,
-0.02221085876226425,
0.05597817152738571,
-0.06815691292285919,
-0.007250... |
returns to prepregnancy levels over the\nfollowing 1 –2 weeks. For individuals tak-\ning insulin, particular attention shouldbe directed to hypoglycemia prevention\nin the setting of breastfeeding and er-\nratic sleep and eating schedules (143).\nLactation\nConsidering the immediate nutritional andimmunological bene fit... | [
-0.004100696183741093,
0.013011280447244644,
-0.07711762189865112,
0.11901229619979858,
0.013186595402657986,
0.03897610679268837,
0.004275375045835972,
0.006494447588920593,
-0.11450327932834625,
-0.01699570007622242,
-0.037206582725048065,
0.050242941826581955,
-0.04116203635931015,
-0.0... |
for the baby, all mothers, including thosewith diabetes, should be supported in at-tempts to breastfeed. An analysis of 28systematic reviews and meta-analyses of\nassociations between breastfeeding and\noutcomes in children found that breast-feeding was associated with numeroushealth bene fits for children such as re- | [
0.01929527334868908,
-0.012746521271765232,
-0.0831170603632927,
0.09466160088777542,
0.04134436324238777,
0.0519520603120327,
0.05413967743515968,
0.02475728653371334,
-0.0870278850197792,
-0.0035716656129807234,
-0.049392007291316986,
0.019950376823544502,
-0.07826677709817886,
-0.022508... |
duced infant mortality due to infectiousdiseases at <6m o n t h so fa g e( o d d sr a t i o\n[OR] 0.22 –0.59 across studies), reduced\nrespiratory infections in children aged\n<2 years, and reduced asthma or wheez-\ni n gi nc h i l d r e na g e d5 –18 years (OR 0.91, | [
-0.003341929754242301,
0.06498405337333679,
0.033852189779281616,
-0.005984024610370398,
0.047763291746377945,
0.04731869697570801,
0.007926275953650475,
0.13335615396499634,
-0.06874227523803711,
0.09969346970319748,
0.057941168546676636,
0.03850845247507095,
0.03665979206562042,
0.042205... |
i n gi nc h i l d r e na g e d5 –18 years (OR 0.91,\n0.85– 0.98) (144). The same analysis foundS290 Management of Diabetes in Pregnancy Diabetes Care Volume 47, Supplement 1, January 2024\n©AmericanDiabetesAssociation | [
-0.04787754267454147,
0.031094806268811226,
-0.026593394577503204,
0.06465382874011993,
0.0024553672410547733,
0.01360755879431963,
-0.016339316964149475,
0.0947078987956047,
-0.06064116954803467,
0.012956592254340649,
-0.05556846782565117,
0.021347731351852417,
-0.07069586217403412,
-0.02... |
that breastfeeding was associated with\nimproved maternal health outcomes in-cluding reduced risks of breast cancer\n(OR 0.81 [95% CI 0.77 –0.86]), ovarian\nc a n c e r( O R0 . 7 0[ 9 5 %C I0 . 6 4 –0.75]), and\ntype 2 diabetes (OR 0.68 [95% CI 0.57 –\n0.82]). Breastfeeding may also confer\nlonger-term metabolic bene fi... | [
0.0047736698761582375,
0.012817589566111565,
-0.08498522639274597,
0.0865938737988472,
0.06855539232492447,
0.041090670973062515,
-0.017287371680140495,
0.04680648818612099,
-0.07573723047971725,
-0.053222205489873886,
-0.020062118768692017,
0.0491468608379364,
-0.042921990156173706,
-0.04... |
longer-term metabolic bene fits to both\nmother (145) and offspring (146). Breast-feeding reduces the risk of developing\ntype 2 diabetes in mothers with previous\nGDM (145). It may improve the metabolicrisk factors of offspring, but more studies\nare needed (147). However, lactation can\nincrease the risk of overnight ... | [
0.024316169321537018,
0.05692411586642265,
-0.046092092990875244,
0.05514192208647728,
0.05206168070435524,
0.03986474499106407,
-0.03142838925123215,
0.037332698702812195,
-0.09217308461666107,
-0.009785130620002747,
-0.046029798686504364,
0.01789616420865059,
-0.06234697625041008,
0.0083... |
increase the risk of overnight hypoglyce-\nmia, and insulin dosing may need to be\nadjusted.\nContraception\nA major barrier to effective preconcep-tion care is the fact that the majority\nof pregnancies are unplanned. Planning\npregnancy is critical in individuals with\npreexisting diabetes to achieve the opti- | [
-0.02623692713677883,
0.10762175172567368,
-0.03562780097126961,
0.05827522650361061,
0.009772252291440964,
0.07934258133172989,
0.025949938222765923,
0.05198125168681145,
-0.05981792137026787,
0.007215337827801704,
-0.053204625844955444,
0.040733542293310165,
-0.1041162759065628,
0.001226... |
preexisting diabetes to achieve the opti-\nmal glycemic goals necessary to preventcongenital malformations and reduce\nthe risk of other complications. There-\nfore, all individuals with diabetes of\nchildbearing potential should have fam-\nily planning options reviewed at regularintervals to make sure that effective | [
-0.02569425478577614,
0.06709826737642288,
-0.02931901253759861,
0.027063526213169098,
-0.07430582493543625,
0.02737610414624214,
0.06620430946350098,
0.06464278697967529,
-0.06612921506166458,
0.006586089730262756,
-0.01214679703116417,
0.04785368964076042,
-0.10101061314344406,
0.0064488... |
contraception is implemented and main-\ntained. This applies to individuals in the\nimmediate postpartum period. Individu-\nals with diabetes have the same contra-ception options and recommendations as\nthose without diabetes. Long-acting, re-\nversible contraception may be ideal for\nindividuals with diabetes and chil... | [
-0.03871600329875946,
0.06934545934200287,
-0.08177632093429565,
0.03738771006464958,
-0.019311636686325073,
0.10988298803567886,
0.03133251890540123,
0.0676993876695633,
-0.004449182190001011,
0.04678351432085037,
0.004167633596807718,
0.10332851111888885,
-0.07978935539722443,
-0.0415712... |
individuals with diabetes and childbear-\ning potential. The risk of an unplannedpregnancy outweighs the risk of any cur-\nrently available contraception option.\nReferences\n1. Dabelea D, Hanson RL, Lindsay RS, et al.\nIntrauterine exposure to diabetes conveys risks\nfor type 2 diabetes and obesity: a study of | [
-0.06384062767028809,
0.0620521605014801,
-0.0850195586681366,
0.06627616286277771,
0.020717374980449677,
0.09594272822141647,
0.05966508761048317,
0.10922885686159134,
-0.00901647750288248,
0.049743879586458206,
-0.02645326592028141,
0.055570732802152634,
-0.0792231410741806,
-0.022166468... |
for type 2 diabetes and obesity: a study of\ndiscordant sibships. Diabetes 2000;49:2208 –2211\n2. Holmes VA, Young IS, Patterson CC, et al.;Diabetes and Pre-eclampsia Intervention Trial StudyGroup. Optimal glycemic control, pre-eclampsia,\na n dg e s t a t i o n a lh y p e r t e n s i o ni nw o m e nw i t ht y p e1 | [
0.011495348997414112,
-0.011545231565833092,
0.02461851015686989,
0.06379871070384979,
-0.02675258368253708,
0.03871854767203331,
0.021487127989530563,
0.11606872081756592,
-0.044985029846429825,
-0.040844231843948364,
-0.004329195711761713,
0.04827608913183212,
-0.07256273180246353,
-0.07... |
diabetes in the diabetes and pre-eclampsia inter-vention trial. Diabetes Care 2011;34:1683– 1688\n3. Guerin A, Nisenbaum R, Ray JG. Use ofmaternal GHb concentration to estimate the risk\nof congenital anomalies in the offspring of women\nwith prepregnancy diabetes. Diabetes Care 2007;30:1920– 1925 | [
-0.011537542566657066,
0.04993207007646561,
-0.04890632629394531,
0.02708619460463524,
-0.03281813859939575,
0.07762447744607925,
0.012934581376612186,
0.07827875763177872,
-0.06846009194850922,
0.05260404944419861,
-0.02585344947874546,
0.04778313636779785,
-0.06870795786380768,
-0.067499... |
with prepregnancy diabetes. Diabetes Care 2007;30:1920– 1925\n4. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse\npregnancy outcome in 933 women with type 1\ndiabetes. Diabetes Care 2009;32:1046 –10485. Suhonen L, Hiilesmaa V, Teramo K. Glycaemic\ncontrol during early pregnancy... | [
-0.04160887748003006,
0.014395464211702347,
-0.05861793830990791,
0.07001184672117233,
-0.058037396520376205,
0.01732260175049305,
0.05496887117624283,
0.101945661008358,
-0.016142968088388443,
0.029200315475463867,
-0.0507233552634716,
0.08076636493206024,
-0.11324837803840637,
-0.0917697... |
control during early pregnancy and fetal mal-\nformations in women with type I diabetes mellitus.\nDiabetologia 2000;43:79– 82\n6. Nielsen GL, Møller M, Sørensen HT. HbA1c in\nearly diabetic pregnancy and pregnancy out-comes: a Danish population-based cohort studyof 573 pregnancies in women with type 1 diabetes.Diabete... | [
-0.003060608636587858,
0.053556717932224274,
-0.07350210100412369,
0.054169561713933945,
-0.015214654617011547,
0.08774295449256897,
0.04739485681056976,
0.06662487238645554,
-0.01281676534563303,
0.030079416930675507,
-0.046653084456920624,
0.004087003413587809,
-0.11097762733697891,
-0.1... |
7. Ludvigsson JF, Neovius M, S €oderling J, et al.\nMaternal glycemic control in type 1 diabetes andthe risk for preterm birth: a population-basedcohort study. Ann Intern Med 2019;170:691– 701\n8. Wahabi HA, Alzeidan RA, Bawazeer GA, Alansari\nLA, Esmaeil SA. Preconception care for diabetic | [
0.010088506154716015,
0.04566673934459686,
-0.06442394107580185,
0.0743795707821846,
-0.030072079971432686,
0.05363894999027252,
0.05137525871396065,
0.07889246195554733,
-0.046052590012550354,
0.062333207577466965,
-0.02153250202536583,
0.05717754736542702,
-0.09988262504339218,
-0.102619... |
LA, Esmaeil SA. Preconception care for diabetic\nwomen for improving maternal and fetal out-comes: a systematic review and meta-analysis.BMC Pregnancy Childbirth 2010;10:63\n9. Charron-Prochownik D, Sereika SM, Becker D, | [
-0.013226761482656002,
0.05558667331933975,
-0.06949010491371155,
0.06719909608364105,
-0.012621289119124413,
0.08697357028722763,
-0.01421046070754528,
0.05682605132460594,
0.0032821176573634148,
0.06327540427446365,
-0.025833413004875183,
0.0660291537642479,
-0.1161695271730423,
-0.08195... |
9. Charron-Prochownik D, Sereika SM, Becker D,\net al. Long-term effects of the booster-enhancedREADY-Girls preconception counseling programon intentions and behaviors for family planningin teens with diabetes. Diabetes Care 2013;36:3870– 3874\n10. ACOG Committee Opinion No. 762: Pre-pregnancy counseling. Obstet Gyneco... | [
-0.05635811388492584,
0.0470815971493721,
-0.041615407913923264,
0.0472712442278862,
0.003184085013344884,
0.07698734104633331,
0.028247496113181114,
0.08424040675163269,
-0.024738239124417305,
0.008403895422816277,
0.03202245756983757,
0.10540615767240524,
-0.07438620924949646,
-0.0415620... |
e78–e89\n11. Peterson C, Grosse SD, Li R, et al. Preven-\ntable health and cost burden of adverse birthoutcomes associated with pregestational dia-betes in the United States. Am J Obstet Gynecol2015;212:74.e1 –74.e9 | [
-0.023486563935875893,
0.0726667046546936,
-0.0393989123404026,
-0.002427823608741164,
-0.01519270334392786,
0.08872746676206589,
0.03744504973292351,
0.12581677734851837,
0.012783628888428211,
0.07153675705194473,
-0.006472023669630289,
0.011572052724659443,
-0.0584852434694767,
-0.042584... |
12. Britton LE, Hussey JM, Berry DC, Crandell JL,Brooks JL, Bryant AG. Contraceptive Use amongwomen with prediabetes and diabetes in a USnational sample. J Midwifery Womens Health2019;64:36– 45\n13. Morris JR, Tepper NK. Description and com-\nparison of postpartum use of effective contra- | [
-0.06430698186159134,
0.031192630529403687,
-0.04990864545106888,
0.053077809512615204,
0.012495404109358788,
0.10467825084924698,
0.06875097006559372,
0.0888531357049942,
-0.03730254992842674,
0.03686191886663437,
-0.024205876514315605,
0.07252895832061768,
-0.07062462717294693,
-0.077109... |
parison of postpartum use of effective contra-\nception among women with and without diabetes.Contraception 2019;100:474– 479\n14. Goldstuck ND, Steyn PS. The intrauterinedevice in women with diabetes mellitus type Iand II: a systematic review. ISRN Obstet Gynecol2013;2013:814062\n15. Wu JP , Moniz MH, Ursu AN. Long-ac... | [
-0.019608447328209877,
0.038610029965639114,
-0.08553414791822433,
0.06322503089904785,
-0.022898240014910698,
0.05052320659160614,
0.010561072267591953,
0.08035612106323242,
0.004832520615309477,
0.06534397602081299,
-0.011289888992905617,
0.10978705435991287,
-0.08617723733186722,
-0.053... |
15. Wu JP , Moniz MH, Ursu AN. Long-acting re-\nversible contraception-highly ef ficacious, safe,\nand underutilized. JAMA 2018;320:397– 398\n16. American College of Obstetricians and Gyne-cologists ’Committee on Practice Bulletins —\nObstetrics. ACOG Practice Bulletin No. 201:Pregestational Diabetes Mellitus. Obstet Gy... | [
-0.044050320982933044,
0.02692909725010395,
-0.08374578505754471,
0.046381957828998566,
-0.011797693558037281,
0.06077684462070465,
0.061940886080265045,
0.09084396809339523,
0.01637302152812481,
0.056439198553562164,
-0.03757542744278908,
0.09606708586215973,
-0.09112213551998138,
-0.0242... |
17. AmericanDiabetes Association. Diabetes andReproductive Health for Girls. 2016. Accessed 25September 2023. Available from https://diabetes.org/sites/default/ files/2021-06/16_ready_girls\n_book_proof_4.15.16%5B1%5D.pdf\n18. Wahabi HA, Fayed A, Esmaeil S, et al. | [
0.005436954088509083,
0.04593411087989807,
-0.010005512274801731,
0.09895196557044983,
-0.04050841182470322,
0.047015201300382614,
0.07558567821979523,
-0.020268134772777557,
-0.09614834189414978,
0.0436255969107151,
0.029178446158766747,
0.02555343508720398,
-0.03384516388177872,
-0.02719... |
18. Wahabi HA, Fayed A, Esmaeil S, et al.\nSystematic review and meta-analysis of the effe-ctiveness of pre-pregnancy care for women withdiabetes for improving maternal and perinatal\noutcomes. PLoS One 2020;15:e0237571\n19. Alexander EK, Pearce EN, Brent GA, et al. | [
-0.02742745913565159,
-0.02606193721294403,
-0.031078258529305458,
0.07925967872142792,
0.008081934414803982,
0.0756102129817009,
0.03942041099071503,
0.05109018087387085,
-0.04114323854446411,
0.054077714681625366,
-0.0688624456524849,
0.06765752285718918,
-0.11687904596328735,
-0.0611580... |
19. Alexander EK, Pearce EN, Brent GA, et al.\n2017 guidelines of the American Thyroid Asso-ciation for the diagnosis and management ofthyroid disease during pregnancy and the post-partum. Thyroid 2017;27:315 –389 | [
-0.03686081990599632,
0.00014302930503617972,
0.039054591208696365,
-0.041066594421863556,
0.09336332231760025,
0.014537396840751171,
-0.017290422692894936,
0.028012339025735855,
-0.05391231179237366,
0.03641059994697571,
-0.012798565439879894,
-0.02507617138326168,
-0.039419662207365036,
... |
20. Ramos DE. Preconception health: changingthe paradigm on well-woman health. Obstet GynecolClin North Am 2019;46:399 –40821. Obesity in pregnancy: ACOG Practice Bulletin,\nNumber 230. Obstet Gynecol 2021;137:e128 –e144\n22. Relph S, Patel T, Delaney L, Sobhy S, Thanga- | [
-0.02890089899301529,
0.06986813992261887,
-0.022949540987610817,
0.12112089991569519,
-0.006547975819557905,
0.0646873265504837,
-0.010271929204463959,
0.061745740473270416,
-0.019882474094629288,
0.042485859245061874,
0.025194566696882248,
0.031088514253497124,
-0.08573030680418015,
-0.0... |
22. Relph S, Patel T, Delaney L, Sobhy S, Thanga-\nratinam S. Adverse pregnancy outcomes in womenwith diabetes-related microvascular disease andrisks of disease progression in pregnancy: Asystematic review and meta-analysis. PLoS Med\n2021;18:e1003856\n23. Bullo M, Tschumi S, Bucher BS, Bianchetti | [
-0.018120404332876205,
0.03156007081270218,
-0.0858021005988121,
0.08734510838985443,
0.01421796903014183,
0.026060622185468674,
-0.009165046736598015,
0.12814821302890778,
-0.004704767372459173,
0.06271373480558395,
-0.06682387739419937,
0.002662831684574485,
-0.0969695970416069,
-0.03900... |
2021;18:e1003856\n23. Bullo M, Tschumi S, Bucher BS, Bianchetti\nMG, Simonetti GD. Pregnancy outcome followingexposure to angiotensin-converting enzymeinhibitors or angiotensin receptor antagonists:a systematic review. Hypertension 2012;60:444–450 | [
-0.02933190017938614,
0.010843814350664616,
-0.042347464710474014,
0.08332886546850204,
0.077120341360569,
0.03376148268580437,
-0.08805868774652481,
0.10271470993757248,
-0.036095671355724335,
0.01977911777794361,
-0.03013470582664013,
-0.05435599759221077,
-0.08752074092626572,
-0.004872... |
24. Bateman BT, Hernandez-Diaz S, Fischer MA,et al. Statins and congenital malformations:cohort study. BMJ 2015;350:h1035\n2 5 .T a g u c h iN ,R u b i nE T ,H o s o k a w aA ,e ta l .\nPrenatal exposure to HMG-CoA reductase inhibitors:effects on fetal and neonatal outcomes. Reprod\nToxicol 2008;26:175 –177 | [
-0.06884633749723434,
-0.008595215156674385,
-0.09631084650754929,
0.04068493843078613,
0.01906263269484043,
0.053342051804065704,
-0.08436907827854156,
0.14731478691101074,
-0.04332314804196358,
0.04429586976766586,
-0.02684253640472889,
0.056973472237586975,
-0.037722378969192505,
0.0069... |
Toxicol 2008;26:175 –177\n26. Widyaputri F, Rogers SL, Kandasamy R, Shub\nA, Symons RCA, Lim LL. Global estimates ofdiabetic retinopathy prevalence and progressionin pregnant women with preexisting diabetes: asystematic review and meta-analysis. JAMAOphthalmol 2022;140:486 –494 | [
0.00972827523946762,
-0.05681709945201874,
-0.043558117002248764,
0.07845035195350647,
0.059276554733514786,
0.022527307271957397,
0.07830163836479187,
0.1309581995010376,
-0.03765273466706276,
0.07544209808111191,
-0.024132899940013885,
-0.03570251911878586,
-0.060177262872457504,
0.03219... |
27. Neoh SL, Grisoni JA, Feig DS; CONCEPTTCollaborative Group. Dietary intakes of womenwith type 1 diabetes before and during pregnancy:ap r e - s p e c i fied secondary subgroup analysis among\nCONCEPTT participants. Diabet Med 2020;37:1841 –1848\n28. Marshall NE, Abrams B, Barbour LA, et al.\nThe importance of nutriti... | [
-0.03513416275382042,
0.01625026762485504,
-0.05201505124568939,
0.07013895362615585,
0.028614960610866547,
0.07248374074697495,
0.09261535108089447,
0.028212150558829308,
-0.06015511229634285,
-0.005980790127068758,
-0.0401618592441082,
0.0037826152984052896,
-0.1292308270931244,
-0.07369... |
The importance of nutrition in pregnancy and\nlactation: lifelong consequences. Am J ObstetGynecol 2022;226:607– 632\n29. Garc /C19ıa-Patterson A, Gich I, Amini SB, Catalano\nPM, de Leiva A, Corcoy R. Insulin requirementsthroughout pregnancy in women with type 1\ndiabetes mellitus: three changes of direction.\nDiabetol... | [
-0.024583397433161736,
0.0264871995896101,
-0.04498345032334328,
0.0879342183470726,
0.022860543802380562,
0.060098595917224884,
0.04365546628832817,
-0.002418969525024295,
-0.0757245421409607,
-0.02577780932188034,
-0.05135641247034073,
0.03892155736684799,
-0.14044098556041718,
-0.041500... |
Diabetologia 2010;53:446– 451\n30. Mathiesen JM, Secher AL, Ringholm L, et al.C h a n g e si nb a s a lr a t e sa n db o l u sc a l c u l a t o rs e t t i n g sin insulin pumps during pregnancy in women withtype 1 diabetes. J Matern Fetal Neonatal Med\n2014;27:724 –728\n31. Best Practice Guide: using diabetes technolog... | [
-0.05771513283252716,
0.002000328851863742,
-0.06713186949491501,
-0.016287321224808693,
-0.07367268949747086,
0.015148572623729706,
0.046487752348184586,
0.07081359624862671,
-0.07656163722276688,
-0.023008879274129868,
-0.06336961686611176,
0.08549904078245163,
-0.08811503648757935,
-0.0... |
2014;27:724 –728\n31. Best Practice Guide: using diabetes technology\nin pregnancy. 2020. Accessed 11 August 2023.Available from https://abcd.care/sites/abcd.care/files/site_uploads/Resources/DTN/BP-Pregnancy-\nDTN-V2.0.pdf\n32. Padmanabhan S, Lee VW , Mclean M, et al.\nThe association of falling insulin requirements | [
-0.04325689375400543,
-0.012950990349054337,
-0.06625722348690033,
0.036328818649053574,
-0.0261800866574049,
0.059161439538002014,
-0.001115486491471529,
0.09320114552974701,
-0.10981041193008423,
-0.016238821670413017,
-0.07022193819284439,
-0.016358673572540283,
-0.08743947744369507,
0.... |
The association of falling insulin requirements\nwith maternal biomarkers and placental dys-function: a prospective study of women withpreexisting diabetes in pregnancy. Diabetes Care2017;40:1323 –1330\n33. de Veciana M, Major CA, Morgan MA, et al.\nPostprandial versus preprandial blood glucose | [
-0.024694539606571198,
0.028953835368156433,
-0.04772927612066269,
0.08039858937263489,
0.04667140915989876,
0.04223918542265892,
0.017070816829800606,
0.09551569819450378,
-0.060826625674963,
-0.004080918617546558,
-0.09191378206014633,
-0.017401278018951416,
-0.09208502620458603,
-0.0232... |
Postprandial versus preprandial blood glucose\nmonitoring in women with gestational diabetesmellitus requiring insulin therapy. N Engl J Med1995;333:1237 –1241\n34. Jovanovic-Peterson L, Peterson CM, ReedGF, et al. Maternal postprandial glucose levelsand infant birth weight: the Diabetes in Early\nPregnancy Study. Am J... | [
-0.05252254754304886,
0.08299162983894348,
-0.1152515560388565,
0.06379823386669159,
-0.024194791913032532,
0.055210426449775696,
0.04268937557935715,
0.08193426579236984,
-0.01770004816353321,
0.02234254591166973,
-0.051014967262744904,
0.07527448236942291,
-0.11192873865365982,
-0.088939... |
Pregnancy Study. Am J Obstet Gynecol 1991;164:\n103– 111\n35. ACOG Practice Bulletin No. 190: GestationalDiabetes Mellitus. Obstet Gynecol 2018;131:e49–e64diabetesjournals.org/care Management of Diabetes in Pregnancy S291\n©AmericanDiabetesAssociation | [
-0.015112379565834999,
0.04035472497344017,
-0.0507788322865963,
0.028544656932353973,
-0.014483148232102394,
0.05926159396767616,
0.014624254778027534,
0.08728104829788208,
-0.053308021277189255,
0.024886466562747955,
-0.06319810450077057,
0.0028168591670691967,
-0.1124950721859932,
-0.05... |
16. Diabetes Care in the Hospital:\nStandards of Care in Diabetes—\n2024\nDiabetes Care 2024;47(Suppl. 1):S295 –S306 |https://doi.org/10.2337/dc24-S016American Diabetes Association\nProfessional Practice Committee *\nThe American Diabetes Association (ADA) “Standards of Care in Diabetes ”includes | [
0.010850194841623306,
0.02899003028869629,
-0.043215490877628326,
0.045990217477083206,
-0.05549323558807373,
0.03763871267437935,
0.01179804652929306,
0.02734426222741604,
-0.04802357032895088,
-0.05209753289818764,
-0.06882543861865997,
0.054066918790340424,
-0.0884341225028038,
-0.00722... |
the ADA ’s current clinical practice recommendations and is intended to provide the\ncomponents of diabetes care, general treatment goals and guidelines, and tools to | [
-0.04139997065067291,
0.0067419796250760555,
-0.08455739915370941,
0.06411178410053253,
-0.05609036609530449,
0.022022750228643417,
0.043380189687013626,
0.06556293368339539,
-0.0767926424741745,
-0.07625574618577957,
-0.05552008002996445,
0.04925420135259628,
-0.11957837641239166,
0.03734... |
evaluate quality of care. Members of the ADA Professional Practice Committee, aninterprofessional expert committee, are responsible for updating the Standards ofCare annually, or more frequently as warranted. For a detailed description ofADA standards, statements, and reports, as well as the evidence-grading systemfor ... | [
-0.06068830192089081,
-0.0686749666929245,
-0.051834482699632645,
0.07729093730449677,
-0.0811145082116127,
-0.0037800862919539213,
-0.015805207192897797,
0.055980246514081955,
-0.05150723457336426,
0.020894693210721016,
-0.05676857382059097,
-0.0019603075925260782,
-0.07326869666576385,
0... |
as well as the evidence-grading systemfor ADA ’s clinical practice recommendations and a full list of Professional Prac- | [
-0.055962588638067245,
-0.06687068939208984,
-0.0974741205573082,
0.02399381250143051,
-0.03063320554792881,
0.021758202463388443,
0.014808167703449726,
0.12367026507854462,
-0.07161430269479752,
0.022293295711278915,
0.02310752682387829,
0.03775642067193985,
-0.08968637883663177,
0.102342... |
tice Committee members, please refer to Introduction and Methodology. Read-ers who wish to comment on the Standards of Care are invited to do so atprofessional.diabetes.org/SOC.\nAmong hospitalized individuals, hyperglycemia, hypoglycemia, and glucose variability | [
-0.014227979816496372,
0.0031435852870345116,
-0.046158187091350555,
0.04796123504638672,
-0.11692580580711365,
0.001690388424322009,
0.00943251047283411,
0.07404252141714096,
-0.046734992414712906,
-0.029267961159348488,
-0.07046203315258026,
0.0040732575580477715,
-0.0906125009059906,
0.... |
are associated with adverse outcomes, including increased morbidity and mortality(1). Identi fication and careful management of people with diabetes and dysglycemia\nduring hospitalization has direct and immediate bene fits. Diabetes management in\nthe inpatient setting is facilitated by identi fication and treatment of h... | [
-0.01758693903684616,
0.07856596261262894,
-0.018149569630622864,
0.02967412956058979,
-0.06975387036800385,
-0.008852867409586906,
0.09137579053640366,
0.08485725522041321,
0.0038985596038401127,
-0.027381431311368942,
-0.006930335890501738,
0.05714651197195053,
-0.03334895521402359,
-0.0... |
prior to elective procedures, a dedicated inpatient diabetes management service ap-\nplying validated standards of care, and a proactive transition plan for outpatient dia-\nbetes care with timely prearranged follow-up appointments. These steps canimprove outcomes, shorten hospital stays, and reduce the need for readmi... | [
-0.06972084194421768,
0.07714073359966278,
-0.0244694035500288,
0.007906352169811726,
-0.10083707422018051,
0.03942194953560829,
0.037099093198776245,
0.012070606462657452,
0.006883786525577307,
0.014252517372369766,
-0.0020023926626890898,
0.0830322727560997,
-0.05749230831861496,
0.00456... |
emergency department visits. For older hospitalized individuals or for people with di-\nabetes in long-term care facilities, please see Section 13, “Older Adults. ”\nHOSPITAL CARE DELIVERY STANDARDS\nRecommendations\n16.1 Perform an A1C test on all people with diabetes or hyperglycemia (random | [
0.028018785640597343,
0.013707630336284637,
0.01709691807627678,
0.0404541939496994,
-0.05656718462705612,
-0.01387972105294466,
0.011058646254241467,
0.013834883458912373,
-0.039413806051015854,
-0.009925964288413525,
0.011631160974502563,
0.006676880177110434,
-0.0868121087551117,
-0.014... |
blood glucose >140 mg/dL [ >7.8 mmol/L]) admitted to the hospital if no A1C test\nresult is available from the prior 3 months. B\n16.2 Institutions should implement protocols using validated written or comput-\nerized provider order entry sets for management of dysglycemia in the hospital | [
-0.02966192550957203,
0.07336704432964325,
-0.04148995876312256,
-0.04768352955579758,
-0.09177082777023315,
-0.01765809953212738,
-0.01119889598339796,
0.0858902707695961,
-0.025882452726364136,
0.022987736389040947,
0.01308521069586277,
-0.016826966777443886,
-0.05977950245141983,
0.0211... |
(including emergency department, intensive care unit [ICU] and non-ICU wards,gynecology-obstetrics/delivery units, dialysis suites, and behavioral health units)that allow for a personalized approach, including glucose monitoring, insulin and/or noninsulin therapy, hypoglycemia management, diabetes self-management educa... | [
-0.044653765857219696,
0.002169456332921982,
-0.05377999320626259,
0.002674711402505636,
-0.05826758220791817,
-0.02837555855512619,
0.011531985364854336,
0.0013269975315779448,
0.010128474794328213,
-0.015152271836996078,
-0.019303450360894203,
0.0009280511876568198,
-0.04885616526007652,
... |
management, diabetes self-management educa-tion, nutrition recommendations, and transitions of care. B | [
-0.041150081902742386,
0.01155882328748703,
-0.03406596556305885,
0.08459976315498352,
-0.03935613855719566,
0.001266929553821683,
0.033231668174266815,
-0.0018251523142680526,
-0.03144355118274689,
-0.052471574395895004,
-0.0007199724786914885,
0.011194082908332348,
-0.13501553237438202,
... |
Considerations on Admission\nHigh-quality hospital care for diabetes requires standards for care delivery, which are\nbest implemented using structured order sets and quality improvement strategies for*A complete list of members of the American\nDiabetes Association Professional Practice Committeecan be found at https:... | [
0.004668526817113161,
0.02124461904168129,
-0.016328245401382446,
-0.012847174890339375,
-0.11124633252620697,
0.020805804058909416,
-0.027753721922636032,
0.03200582414865494,
-0.018560398370027542,
-0.021597443148493767,
-0.0529424250125885,
0.07793173938989639,
-0.05217811465263367,
-0.... |
Duality of interest information for each author is\navailable at https://doi.org/10.2337/dc24-SDIS.\nSuggested citation: American Diabetes Association\nProfessional Practice Committee. 16. Diabetes carein the hospital: Standards of Care in Diabetes —\n2024. Diabetes Care 2024;47(Suppl. 1):S295 –S306 | [
0.011895766481757164,
0.01563691906630993,
-0.08035445213317871,
0.038503386080265045,
-0.007369823753833771,
0.04195496067404747,
0.012920252978801727,
0.09660674631595612,
0.007754421327263117,
-0.03721547871828079,
-0.08376051485538483,
0.10293073952198029,
-0.06333392858505249,
-0.0131... |
2024. Diabetes Care 2024;47(Suppl. 1):S295 –S306\n© 2023 by the American Diabetes Association.Readers may use this article as long as thework is properly cited, the use is educationaland not for pro fit, and the work is not altered. | [
-0.07238271832466125,
0.03040437400341034,
-0.03692036494612694,
0.02635294571518898,
-0.04619007185101509,
0.07471755892038345,
-0.05963338166475296,
0.05559258908033371,
-0.03523005545139313,
-0.030036769807338715,
-0.06654306501150131,
0.1285448521375656,
-0.047525253146886826,
-0.03779... |
More information is available at https://www.diabetesjournals.org/journals/pages/license.16. DIABETES CARE IN THE HOSPITALDiabetes Care Volume 47, Supplement 1, January 2024 S295\n©AmericanDiabetesAssociation | [
0.048789165914058685,
-0.015965476632118225,
-0.07095527648925781,
0.06907258182764053,
-0.05489010363817215,
0.03488444909453392,
-0.001218614517711103,
0.04828657954931259,
-0.03409493342041969,
-0.04308387264609337,
-0.07798516005277634,
0.08199843019247055,
-0.04784606769680977,
-0.018... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.